Schroeder Quoted on Los Angeles’ ‘Ban-the-Box’ Ordinance
March 8, 2017
Hotel Management Magazine
Partner Don Schroeder was quoted in a Hotel Management article, “How ‘Ban-the-Box’ Ordinances Complicate Hiring at Hotels,” covering the success rates of ‘ban-the-box’ ordinances and in what position it places employers.
Schroeder explained: “You want to give people a second chance, that’s the point of this, but being able to ask about certain offenses would prove to be somewhat valuable information for an employer. In some ways, it cuts off [an employer’s] liability for gross negligence if the law prevents them from asking certain questions… but relating to probations, fines, prison stays or parole, it’s really broad not to ask any questions there. If you go to that length, you are tying an employer’s hands.”
Schroeder explained: “You want to give people a second chance, that’s the point of this, but being able to ask about certain offenses would prove to be somewhat valuable information for an employer. In some ways, it cuts off [an employer’s] liability for gross negligence if the law prevents them from asking certain questions… but relating to probations, fines, prison stays or parole, it’s really broad not to ask any questions there. If you go to that length, you are tying an employer’s hands.”
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."